Literature DB >> 23137741

Cardiac management in neuromuscular diseases.

Hugh D Allen1, Philip T Thrush, Timothy M Hoffman, Kevin M Flanigan, Jerry R Mendell.   

Abstract

This article addresses the pathophysiology, diagnostic approaches, and therapeutic options in the more common forms of muscular dystrophy, especially those seen in pediatric and young adult populations. The major emphasis is on the dystrophinopathies because their treatment options are templates for those used in various other forms of dystrophy. Most patients with cardiomyopathy are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, with other agents added as the disease progresses. Destination therapies and transplantation options are mentioned where appropriate. Some dystrophies can have significant conduction abnormalities requiring pacemaker treatment. Others with ventricular tachydysrhythmias may necessitate internal cardiac defibrillator placement.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23137741     DOI: 10.1016/j.pmr.2012.08.001

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  8 in total

1.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

2.  Echocardiographic evaluation of left ventricular systolic function by the M-mode lateral mitral annular plane systolic excursion in patients with Duchenne muscular dystrophy age 0-21 years.

Authors:  Melissa K Webb; Poonam P Thankavel; Claudio Ramaciotti
Journal:  Health Sci Rep       Date:  2020-10-05

3.  A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.

Authors:  Hugh D Allen; Kevin M Flanigan; Philip T Thrush; Igor Dvorchik; Han Yin; Charles Canter; Anne M Connolly; Mark Parrish; Craig M McDonald; Elizabeth Braunlin; Steven D Colan; John Day; Basil Darras; Jerry R Mendell
Journal:  PLoS Curr       Date:  2013-12-12

4.  POPDC1(S201F) causes muscular dystrophy and arrhythmia by affecting protein trafficking.

Authors:  Roland F R Schindler; Chiara Scotton; Jianguo Zhang; Chiara Passarelli; Beatriz Ortiz-Bonnin; Subreena Simrick; Thorsten Schwerte; Kar-Lai Poon; Mingyan Fang; Susanne Rinné; Alexander Froese; Viacheslav O Nikolaev; Christiane Grunert; Thomas Müller; Giorgio Tasca; Padmini Sarathchandra; Fabrizio Drago; Bruno Dallapiccola; Claudio Rapezzi; Eloisa Arbustini; Francesca Romana Di Raimo; Marcella Neri; Rita Selvatici; Francesca Gualandi; Fabiana Fattori; Antonello Pietrangelo; Wenyan Li; Hui Jiang; Xun Xu; Enrico Bertini; Niels Decher; Jun Wang; Thomas Brand; Alessandra Ferlini
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

5.  Evaluation of Echocardiographic Measures of Left Ventricular Function in Patients with Duchenne Muscular Dystrophy: Assessment of Reproducibility and Comparison to Cardiac Magnetic Resonance Imaging.

Authors:  Jonathan H Soslow; Meng Xu; James C Slaughter; Michael Stanley; Kimberly Crum; Larry W Markham; David A Parra
Journal:  J Am Soc Echocardiogr       Date:  2016-08-17       Impact factor: 5.251

Review 6.  Diagnosis of Cardiac Abnormalities in Muscular Dystrophies.

Authors:  Elisabeta Bădilă; Iulia Ioana Lungu; Alexandru Mihai Grumezescu; Alexandru Scafa Udriște
Journal:  Medicina (Kaunas)       Date:  2021-05-12       Impact factor: 2.430

7.  MicroRNA based treatment of cardiomyopathy: not all dystrophies are created equal.

Authors:  Louise R Rodino-Klapac
Journal:  J Am Heart Assoc       Date:  2013-08-22       Impact factor: 5.501

8.  An Overview of Cardiac Management in Neuromuscular Disease.

Authors:  Renee M Hickey; John D Cullen; George M Sachs
Journal:  Open Cardiovasc Med J       Date:  2016-05-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.